Recent Updates
Recently added Catalysts
FTH Positive Sentiment

Faeth Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate PIKTOR in Combination with a Selective Estrogen Receptor Degrader in HR+/HER2- Advanced Breast Cancer

Key Takeaway: Faeth Therapeutics announced a collaboration with Roche to evaluate its lead program, PIKTOR, in combination with giredestrant. This clinical trial targets patients with hormone receptor-positive, HER2-negative advanced breast cancer. The partnership aims to explore the potential benefits of this combination therapy.

Market Sentiment Analysis

POSITIVE FACTORS

  • Faeth Therapeutics collaborates with Roche for clinical trial.
  • Evaluation of PIKTOR with giredestrant in advanced breast cancer.
  • Focus on HR+/HER2- advanced breast cancer treatment.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+52%
120-day peak, hindsight
Typical move
28.8%
average across 2 past catalysts
Cash runway
~40 mo
Low dilution risk
Lead asset
Serabelisib
Phase 2 · HR+ HER2- Breast Cancer

Full Press Release Details

AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that it has entered into a clinical trial collaboration and supply agreement with F. Hoffmann-La Roche Ltd (Roche) to evaluate PIKTOR in combination with the investigational medicine giredestrant in patients with hormone receptor-positive, HER2-negative (HR+/HER2-) advanced breast cancer. Under

Frequently Asked Questions

What is the focus of the Faeth and Roche collaboration?

The collaboration focuses on evaluating PIKTOR with giredestrant in advanced breast cancer.

What type of breast cancer is being targeted?

The trial targets hormone receptor-positive, HER2-negative advanced breast cancer.

Who is involved in the clinical trial collaboration?

Faeth Therapeutics and F. Hoffmann-La Roche Ltd are collaborating.

What is the investigational medicine used in the trial?

The trial evaluates PIKTOR in combination with giredestrant.

Last updated: Nov 16, 2026